Compare Coupang Inc (CPNG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs TransMedics Group Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Coupang Inc is far larger — about 10.1× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 27,703,608). Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and TransMedics Group Inc for 24 Days on average.
| CPNG | TMDX | |
|---|---|---|
Market Cap | $27.70B | $2.74B |
Volume | 27,703,608 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $150.42 |
52-Week Low | $13.75 | $61.99 |
Typical Hold Time | 55 Days | 24 Days |
Enterprise Value | $27.22B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.82, up 6.82% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with positive moving averages and institutional support. Revenue growth remains robust at $34.53 billion for 2025, though profitability metrics show challenges with negative net income margin and ROE. Analyst consensus is strongly bullish with 87.5% buy ratings and a $25.25 price target, representing significant upside potential from current levels.
The investment case hinges on Coupang's dominant South Korean market position and expanding logistics network, but faces headwinds from inconsistent profitability and competitive pressures. While valuation appears reasonable on sales (P/S 0.8), high P/E ratio reflects earnings volatility. Key risks include execution challenges in international expansion and margin pressure from logistics investments. The stock offers growth exposure but requires careful monitoring of profitability trends.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
